Xalatan receives paediatric indication in Europe
Pfizer has announced that Xalatan (latanoprost) has been approved by the European Commission for the reduction of elevated IOP in the treatment of paediatric patients.
Pfizer has announced that Xalatan (latanoprost) has been approved by the European Commission for the reduction of elevated IOP in the treatment of paediatric patients. This is the first time that a prostaglandin analogue has completed safety and efficacy trials in a paediatric population and has been indicated for use in patients aged 18 or younger in Europe.
The EU approval has been based on Phase III and Phase I studies that were contained in Pfizer's Paediatric Investigation Plan as agreed with the European Medicines Agency (EMA) in accordance with the EU Paediatrics Medicines Regulation. As a result of its compliance with these regulations Pfizer can and will apply for a six-month patent protection extension in European countries where it currently has a Supplementary Protection Certificate (SPC).
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.
